Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma, Inc. (Nasdaq: SILO) regularly issues news updates that reflect its dual identity as a developmental-stage biopharmaceutical company and a cryptocurrency treasury company. Its press releases highlight progress in drug development for stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, alongside announcements about its evolving digital assets treasury strategy.
On the biopharmaceutical side, Silo’s news flow centers on SPC-15, an investigational intranasal serotonin 5-HT4 receptor agonist being developed for PTSD and stress-induced anxiety. Recent releases describe IND-enabling toxicology and toxicokinetic work, large animal safety studies, drug-device evaluations of a soft mist nasal spray system, and plans for Phase 1 single ascending dose and multiple ascending dose studies. The company also reports on regulatory strategy, including its intention to pursue the FDA’s 505(b)(2) pathway, and on collaborations with organizations such as Allucent and Columbia University.
News items also cover Silo’s broader pipeline, including SP-26 for fibromyalgia and chronic pain and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Investors following SILO news can expect updates on preclinical data, clinical trial preparations, intellectual property expansion, and strategic academic and CRO partnerships.
In parallel, Silo’s releases describe the launch and build-out of its digital assets treasury. Announcements detail initial purchases of Bitcoin, Ethereum, Solana, and ResearchCoin, the establishment of a Crypto Advisory Board, engagement of Fireblocks for institutional-grade custody and infrastructure, and allocation to the Alphaledger T12 Fund for tokenized real-world asset exposure on the Solana blockchain. Additional disclosures include software and domain acquisitions related to crypto applications and updates on treasury diversification objectives.
Visitors to the SILO news page can use this stream of company-issued information to track clinical milestones, regulatory steps, capital markets activity, and digital asset strategy developments over time.
Silo Pharma, Inc. (OTCQB: SILO) announced a significant milestone as its joint venture partner, Zylo Therapeutics, received its first ketamine shipment, marking the initiation of ketamine loading into the Z-Pod® transdermal technology. CEO Eric Weisblum emphasized that this advancement is pivotal for therapeutic applications of ketamine and could potentially enhance the delivery of psilocybin. Silo Pharma focuses on merging traditional therapies with psychedelic research to address mental health issues such as depression and PTSD.
Englewood Cliffs, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma (OTCQB: SILO), a biopharmaceutical company focused on psychedelics for therapeutic use, reported its third quarter 2021 financial results and business updates. Key highlights include a research agreement with Columbia University for Alzheimer’s therapeutic development, a patent allowance from the U.S. Patent Office for CNS homing peptides, and DEA approval for a joint venture to deliver ketamine. The company has approximately $11 million in working capital and aims to uplist to the Nasdaq, enhancing long-term shareholder value.
Silo Pharma (OTCQB: SILO) has entered a sponsored research agreement with Columbia University to explore options for licensing Alzheimer’s therapeutic assets. Under the leadership of Dr. Christine Ann Denny, the initiative focuses on understanding molecular mechanisms linked to Alzheimer’s disease and memory retrieval. With 5.8 million Americans affected by Alzheimer’s, this collaboration aims to develop innovative treatments using psychedelic compounds, potentially providing significant improvements in cognitive health.
Silo Pharma (OTCQB: SILO) has entered a research agreement with Columbia University focused on developing treatments for Alzheimer’s disease. This partnership involves Dr. Christine Ann Denny, who studies the molecular mechanisms of memory and learning. Silo has the option to license certain assets related to this research, which aims to explore the therapeutic potential of ketamine for improving memory retrieval and addressing cognitive decline. The agreement represents a significant step in Silo's efforts to provide innovative solutions for patients suffering from Alzheimer’s and related conditions.
Silo Pharma (OTCQB: SILO) announced that its joint venture partner, Zylo Therapeutics, received DEA approval to develop Z-pod technology with Ketamine. CEO Eric Weisblum expressed optimism about creating a transdermal Ketamine therapeutic using this patented technology, which may also deliver Psilocybin in a controlled manner. This development aims to provide innovative solutions for patients suffering from depression, PTSD, Parkinson’s, and other neurological disorders. Updates on this partnership are anticipated as milestones are achieved.
Silo Pharma, Inc. (OTCQB: SILO) announced the filing of three Patent Cooperation Treaty (PCT) applications aimed at protecting its intellectual property related to the central nervous system delivery of unique anti-inflammatory therapeutics combined with psilocybin. This step is part of the company’s commitment to research and development in the biopharmaceutical space, specifically targeting conditions like depression and PTSD. The applications focus on the therapeutic potential of psychedelics and anti-inflammatory drugs, expanding possible treatment options for various neurological disorders.
On August 11, 2021, Silo Pharma (OTCQB:SILO) announced that its partner, ZYLO Therapeutics, successfully completed its first inspection with the SC Board of Pharmacy. This milestone enables progress with the Department of Health and Environmental Control towards developing a transdermal Ketamine therapeutic leveraging patented Z-Pod® technology. CEO Eric Weisblum emphasized the significance of this step, highlighting the potential for controlled, time-released delivery of Ketamine or Psilocybin.
Silo Pharma (OTCQB:SILO) announced a significant development in its product pipeline, receiving a notice of allowance for a patent from the United States Patent Office pertaining to its Central Nervous System Homing Peptide. This novel peptide aims to enhance the delivery of psychedelics, including Psilocybin, for therapeutic applications. CEO Eric Weisblum expressed optimism about expanding their intellectual property portfolio to cover markets for potential therapeutic applications, addressing conditions like depression and PTSD.
Silo Pharma, Inc. (OTCQB: SILO) will engage in a nationwide media tour on July 22, aimed at raising awareness about psychedelic medicines and their potential therapeutic benefits for conditions such as mental illness and chronic pain. Sponsored by Radio Media LLC, the tour will feature Dr. Josh Woolley, MD, PhD, discussing ongoing research in psychedelic therapy. The broadcast will reach various stations across the U.S., with recordings available on Silo Pharma's website post-event.
Silo Pharma (OTCQB: SILO) has entered into a Scientific Research Agreement with the University of Maryland, Baltimore, to investigate the efficacy of a novel peptide, ART-1, for delivering dexamethasone to treat rheumatoid arthritis. This study will utilize peptide-guided liposomes to potentially enhance the drug's efficacy and reduce toxicity. CEO Eric Weisblum emphasized the importance of this milestone for accessing a significant market and improving therapeutic targeting. The company aims to develop a technology platform adaptable for other drugs, enhancing treatment options for various conditions.